These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38820447)

  • 41. Investigating hyperoxic effects in the rat brain using quantitative susceptibility mapping based on MRI phase.
    Hsieh MC; Kuo LW; Huang YA; Chen JH
    Magn Reson Med; 2017 Feb; 77(2):592-602. PubMed ID: 26834053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative T
    Harper JG; York EN; Meijboom R; Kampaite A; Thrippleton MJ; Kearns PKA; Valdés Hernández MDC; Chandran S; Waldman AD;
    Eur Radiol; 2024 Jun; 34(6):3826-3839. PubMed ID: 37943312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.
    Schweser F; Raffaini Duarte Martins AL; Hagemeier J; Lin F; Hanspach J; Weinstock-Guttman B; Hametner S; Bergsland N; Dwyer MG; Zivadinov R
    Neuroimage; 2018 Feb; 167():438-452. PubMed ID: 29097315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
    Sinnecker T; Clarke MA; Meier D; Enzinger C; Calabrese M; De Stefano N; Pitiot A; Giorgio A; Schoonheim MM; Paul F; Pawlak MA; Schmidt R; Kappos L; Montalban X; Rovira À; Evangelou N; Wuerfel J;
    JAMA Neurol; 2019 Dec; 76(12):1446-1456. PubMed ID: 31424490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemodynamics of cerebral veins analyzed by 2d and 4d flow mri and ultrasound in healthy volunteers and patients with multiple sclerosis.
    Schuchardt FF; Kaller CP; Strecker C; Lambeck J; Wehrum T; Hennemuth A; Anastasopoulos C; Mader I; Harloff A
    J Magn Reson Imaging; 2020 Jan; 51(1):205-217. PubMed ID: 31102341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic cerebrospinal venous insufficiency is not more prevalent in patients with mild multiple sclerosis: a sonographer-blinded, case-control ultrasound study.
    Chambers B; Chambers J; Cameron H; Macdonell R
    Mult Scler; 2013 May; 19(6):749-56. PubMed ID: 22961213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T.
    Inglese M; Park SJ; Johnson G; Babb JS; Miles L; Jaggi H; Herbert J; Grossman RI
    Arch Neurol; 2007 Feb; 64(2):196-202. PubMed ID: 17296835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.
    Yalachkov Y; Soydaş D; Bergmann J; Frisch S; Behrens M; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2019 May; 30():33-37. PubMed ID: 30735970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive compensation failure in multiple sclerosis.
    Bonnet MC; Allard M; Dilharreguy B; Deloire M; Petry KG; Brochet B
    Neurology; 2010 Oct; 75(14):1241-8. PubMed ID: 20921510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Bsteh G; Hegen H; Teuchner B; Amprosi M; Berek K; Ladstätter F; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2019 Feb; 25(2):196-203. PubMed ID: 29095097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional connectivity dynamics reflect disability and multi-domain clinical impairment in patients with relapsing-remitting multiple sclerosis.
    Romanello A; Krohn S; von Schwanenflug N; Chien C; Bellmann-Strobl J; Ruprecht K; Paul F; Finke C
    Neuroimage Clin; 2022; 36():103203. PubMed ID: 36179389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.
    Burgetova A; Dusek P; Vaneckova M; Horakova D; Langkammer C; Krasensky J; Sobisek L; Matras P; Masek M; Seidl Z
    AJNR Am J Neuroradiol; 2017 Jun; 38(6):1079-1086. PubMed ID: 28450431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability.
    Migliore S; Ghazaryan A; Simonelli I; Pasqualetti P; Squitieri F; Curcio G; Landi D; Palmieri MG; Moffa F; Filippi MM; Vernieri F
    Behav Neurol; 2017; 2017():7404289. PubMed ID: 28912625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unlocking the link: how hippocampal glutathione-glutamate coupling predicts cognitive impairment in multiple sclerosis patients.
    Li F; Zong W; Xin C; Ren F; Li N; Li H; Li X; Wu L; Dai Z; Chen W; Li M; Gao F; Wang G
    Cereb Cortex; 2024 Jan; 34(1):. PubMed ID: 37943724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study.
    Zivadinov R; Schirda C; Dwyer MG; Haacke ME; Weinstock-Guttman B; Menegatti E; Heininen-Brown M; Magnano C; Malagoni AM; Wack DS; Hojnacki D; Kennedy C; Carl E; Bergsland N; Hussein S; Poloni G; Bartolomei I; Salvi F; Zamboni P
    Int Angiol; 2010 Apr; 29(2):158-75. PubMed ID: 20351672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.
    Hagemeier J; Ramanathan M; Schweser F; Dwyer MG; Lin F; Bergsland N; Weinstock-Guttman B; Zivadinov R
    Neuroimage Clin; 2018; 17():530-540. PubMed ID: 29201641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced global brain metabolism but maintained vascular function in amnestic mild cognitive impairment.
    Thomas BP; Sheng M; Tseng BY; Tarumi T; Martin-Cook K; Womack KB; Cullum MC; Levine BD; Zhang R; Lu H
    J Cereb Blood Flow Metab; 2017 Apr; 37(4):1508-1516. PubMed ID: 27389176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.